S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
pixel
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
pixel
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
pixel
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
pixel
Log in
LON:ERGO

Ergomed plc (ERGO.L) Competitors

GBX 1,100
+120.00 (+12.24 %)
(As of 01/26/2021 12:00 AM ET)
Add
Compare
Today's Range
1,020
Now: GBX 1,100
1,100
50-Day Range
945
MA: GBX 1,034.50
1,200
52-Week Range
258
Now: GBX 1,100
1,230
Volume78,136 shs
Average Volume132,834 shs
Market Capitalization£535.91 million
P/E Ratio88.00
Dividend YieldN/A
BetaN/A

Competitors

Ergomed plc (ERGO.L) (LON:ERGO) Vs. PRTC, NCYT, OXB, SLN, SNG, and TILS

Should you be buying ERGO stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Ergomed plc (ERGO.L), including PureTech Health (PRTC), Novacyt S.A. (NCYT.L) (NCYT), Oxford Biomedica plc (OXB.L) (OXB), Silence Therapeutics plc (SLN.L) (SLN), Synairgen plc (SNG.L) (SNG), and Tiziana Life Sciences PLC (TILS.L) (TILS).

Ergomed plc (ERGO.L) (LON:ERGO) and PureTech Health (LON:PRTC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, valuation and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Ergomed plc (ERGO.L) and PureTech Health, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ergomed plc (ERGO.L)0000N/A
PureTech Health00403.00

PureTech Health has a consensus price target of GBX 481.25, indicating a potential upside of 21.68%. Given PureTech Health's higher probable upside, analysts plainly believe PureTech Health is more favorable than Ergomed plc (ERGO.L).

Earnings and Valuation

This table compares Ergomed plc (ERGO.L) and PureTech Health's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ergomed plc (ERGO.L)£73.46 million7.30N/AGBX 12.5088.00
PureTech Health£12.26 million92.19N/AGBX 158.602.49

PureTech Health is trading at a lower price-to-earnings ratio than Ergomed plc (ERGO.L), indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ergomed plc (ERGO.L) and PureTech Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ergomed plc (ERGO.L)N/AN/AN/A
PureTech HealthN/AN/AN/A

Summary

PureTech Health beats Ergomed plc (ERGO.L) on 4 of the 6 factors compared between the two stocks.

Novacyt S.A. (NCYT.L) (LON:NCYT) and Ergomed plc (ERGO.L) (LON:ERGO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

Earnings and Valuation

This table compares Novacyt S.A. (NCYT.L) and Ergomed plc (ERGO.L)'s top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novacyt S.A. (NCYT.L)N/AN/AN/AGBX (26.20)-44.20
Ergomed plc (ERGO.L)£73.46 million7.30N/AGBX 12.5088.00

Novacyt S.A. (NCYT.L) is trading at a lower price-to-earnings ratio than Ergomed plc (ERGO.L), indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Novacyt S.A. (NCYT.L) and Ergomed plc (ERGO.L)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Novacyt S.A. (NCYT.L)N/AN/AN/A
Ergomed plc (ERGO.L)N/AN/AN/A

Analyst Ratings

This is a summary of current recommendations and price targets for Novacyt S.A. (NCYT.L) and Ergomed plc (ERGO.L), as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Novacyt S.A. (NCYT.L)0000N/A
Ergomed plc (ERGO.L)0000N/A

Summary

Ergomed plc (ERGO.L) beats Novacyt S.A. (NCYT.L) on 3 of the 3 factors compared between the two stocks.

Ergomed plc (ERGO.L) (LON:ERGO) and Oxford Biomedica plc (OXB.L) (LON:OXB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Ergomed plc (ERGO.L) and Oxford Biomedica plc (OXB.L), as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ergomed plc (ERGO.L)0000N/A
Oxford Biomedica plc (OXB.L)01202.67

Oxford Biomedica plc (OXB.L) has a consensus target price of GBX 926.67, indicating a potential downside of 6.30%. Given Oxford Biomedica plc (OXB.L)'s higher possible upside, analysts plainly believe Oxford Biomedica plc (OXB.L) is more favorable than Ergomed plc (ERGO.L).

Valuation and Earnings

This table compares Ergomed plc (ERGO.L) and Oxford Biomedica plc (OXB.L)'s top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ergomed plc (ERGO.L)£73.46 million7.30N/AGBX 12.5088.00
Oxford Biomedica plc (OXB.L)£65.94 million12.35N/AGBX (16.40)-60.30

Oxford Biomedica plc (OXB.L) is trading at a lower price-to-earnings ratio than Ergomed plc (ERGO.L), indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ergomed plc (ERGO.L) and Oxford Biomedica plc (OXB.L)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ergomed plc (ERGO.L)N/AN/AN/A
Oxford Biomedica plc (OXB.L)N/AN/AN/A

Silence Therapeutics plc (SLN.L) (LON:SLN) and Ergomed plc (ERGO.L) (LON:ERGO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, dividends and profitability.

Analyst Ratings

This is a summary of current ratings and recommmendations for Silence Therapeutics plc (SLN.L) and Ergomed plc (ERGO.L), as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Silence Therapeutics plc (SLN.L)00103.00
Ergomed plc (ERGO.L)0000N/A

Silence Therapeutics plc (SLN.L) presently has a consensus price target of GBX 605, indicating a potential upside of 4.31%. Given Silence Therapeutics plc (SLN.L)'s higher possible upside, equities research analysts clearly believe Silence Therapeutics plc (SLN.L) is more favorable than Ergomed plc (ERGO.L).

Earnings and Valuation

This table compares Silence Therapeutics plc (SLN.L) and Ergomed plc (ERGO.L)'s gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Silence Therapeutics plc (SLN.L)£1.39 million347.61N/AGBX (28.10)-20.64
Ergomed plc (ERGO.L)£73.46 million7.30N/AGBX 12.5088.00

Silence Therapeutics plc (SLN.L) is trading at a lower price-to-earnings ratio than Ergomed plc (ERGO.L), indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Silence Therapeutics plc (SLN.L) and Ergomed plc (ERGO.L)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Silence Therapeutics plc (SLN.L)N/AN/AN/A
Ergomed plc (ERGO.L)N/AN/AN/A

Synairgen plc (SNG.L) (LON:SNG) and Ergomed plc (ERGO.L) (LON:ERGO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, dividends and profitability.

Analyst Ratings

This is a summary of current ratings and recommmendations for Synairgen plc (SNG.L) and Ergomed plc (ERGO.L), as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Synairgen plc (SNG.L)0000N/A
Ergomed plc (ERGO.L)0000N/A

Earnings and Valuation

This table compares Synairgen plc (SNG.L) and Ergomed plc (ERGO.L)'s gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Synairgen plc (SNG.L)£79,000.004,529.70N/AGBX (5.10)-35.10
Ergomed plc (ERGO.L)£73.46 million7.30N/AGBX 12.5088.00

Synairgen plc (SNG.L) is trading at a lower price-to-earnings ratio than Ergomed plc (ERGO.L), indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Synairgen plc (SNG.L) and Ergomed plc (ERGO.L)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Synairgen plc (SNG.L)N/AN/AN/A
Ergomed plc (ERGO.L)N/AN/AN/A

Summary

Ergomed plc (ERGO.L) beats Synairgen plc (SNG.L) on 3 of the 4 factors compared between the two stocks.

Tiziana Life Sciences PLC (TILS.L) (LON:TILS) and Ergomed plc (ERGO.L) (LON:ERGO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, profitability and dividends.

Profitability

This table compares Tiziana Life Sciences PLC (TILS.L) and Ergomed plc (ERGO.L)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tiziana Life Sciences PLC (TILS.L)N/AN/AN/A
Ergomed plc (ERGO.L)N/AN/AN/A

Valuation and Earnings

This table compares Tiziana Life Sciences PLC (TILS.L) and Ergomed plc (ERGO.L)'s gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tiziana Life Sciences PLC (TILS.L)N/AN/AN/AGBX (5.50)-28.36
Ergomed plc (ERGO.L)£73.46 million7.30N/AGBX 12.5088.00

Tiziana Life Sciences PLC (TILS.L) is trading at a lower price-to-earnings ratio than Ergomed plc (ERGO.L), indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations for Tiziana Life Sciences PLC (TILS.L) and Ergomed plc (ERGO.L), as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tiziana Life Sciences PLC (TILS.L)0000N/A
Ergomed plc (ERGO.L)0000N/A

Summary

Ergomed plc (ERGO.L) beats Tiziana Life Sciences PLC (TILS.L) on 3 of the 3 factors compared between the two stocks.


Ergomed plc (ERGO.L) Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
PureTech Health logo
PRTC
PureTech Health
1.5$395.50+1.6%£1.13 billion£12.26 million2.49Gap Down
NCYT
Novacyt S.A. (NCYT.L)
0.7$1,158.00+2.8%£817.85 millionN/A-44.20
Oxford Biomedica plc (OXB.L) logo
OXB
Oxford Biomedica plc (OXB.L)
0.8$989.00+0.8%£814.15 million£65.94 million-60.30
Silence Therapeutics plc (SLN.L) logo
SLN
Silence Therapeutics plc (SLN.L)
0.8$580.00+4.5%£483.18 million£1.39 million-20.64
Synairgen plc (SNG.L) logo
SNG
Synairgen plc (SNG.L)
0.4$179.00+5.0%£357.85 million£79,000.00-35.10Gap Down
Tiziana Life Sciences PLC (TILS.L) logo
TILS
Tiziana Life Sciences PLC (TILS.L)
0.7$156.00+3.8%£303.60 millionN/A-28.36Gap Up
Bioventix PLC (BVXP.L) logo
BVXP
Bioventix PLC (BVXP.L)
0.8$4,500.00+2.2%£234.42 million£10.31 million32.63Gap Down
ARIX
Arix Bioscience plc (ARIX.L)
1.2$172.50+4.3%£233.93 million£23.47 million12.32
Faron Pharmaceuticals Oy (FARN.L) logo
FARN
Faron Pharmaceuticals Oy (FARN.L)
0.6$422.50+5.9%£198.14 millionN/A-3.86News Coverage
Gap Down
ORPH
Open Orphan plc (ORPH.L)
0.0$24.50+1.0%£163.67 million£10.57 million-7.66
Redx Pharma Plc (REDX.L) logo
REDX
Redx Pharma Plc (REDX.L)
0.9$62.00+4.8%£161.59 million£4.30 million-14.09
DDDD
4D pharma plc (DDDD.L)
0.6$119.50+0.4%£157.01 million£486,000.00-3.78
Mereo BioPharma Group plc (MPH.L) logo
MPH
Mereo BioPharma Group plc (MPH.L)
0.6$26.50+1.9%£138.87 millionN/A-0.21
VSN
Verseon
0.5$74.00+2.0%£127.41 millionN/A-5.17Gap Down
Scancell Holdings plc (SCLP.L) logo
SCLP
Scancell Holdings plc (SCLP.L)
0.9$15.00+3.3%£122.28 millionN/A-12.50High Trading Volume
Verona Pharma plc (VRP.L) logo
VRP
Verona Pharma plc (VRP.L)
0.5$25.94+0.1%£107.53 millionN/A-0.79High Trading Volume
Circassia Group Plc (CIR.L) logo
CIR
Circassia Group Plc (CIR.L)
0.6$25.50+2.0%£101.38 million£55.20 million-2.55
ETX
e-therapeutics plc (ETX.L)
0.8$19.88+2.3%£83.63 million£305,000.00-19.88Gap Down
OKYO
OKYO Pharma Limited (OKYO.L)
0.5$9.29+2.2%£77.35 millionN/A-92.94
OBD
Oxford BioDynamics Plc (OBD.L)
0.5$82.75+2.1%£76.59 million£521,000.00-21.78
C4XD
C4X Discovery Holdings plc (C4XD.L)
0.6$33.50+0.0%£75.83 million£7.06 million-4.14
Destiny Pharma plc (DEST.L) logo
DEST
Destiny Pharma plc (DEST.L)
0.8$120.00+2.9%£71.78 million£305,906.00-10.43Gap Down
ReNeuron Group plc (RENE.L) logo
RENE
ReNeuron Group plc (RENE.L)
0.6$118.50+4.2%£67.36 million£112,000.00-2.58
ANIC
Agronomics Limited (ANIC.L)
0.8$13.40+15.3%£66.91 million£656,377.0019.14News Coverage
Gap Up
SBTX
SkinBioTherapeutics Plc (SBTX.L)
0.4$39.50+2.5%£61.58 millionN/A-32.92News Coverage
Gap Up
OptiBiotix Health Plc (OPTI.L) logo
OPTI
OptiBiotix Health Plc (OPTI.L)
0.4$62.50+6.4%£54.96 million£687,584.00-27.17
HVO
Hvivo
0.5$54.17+0.6%£45.32 million£12.09 million-2.71
IXICO plc (IXI.L) logo
IXI
IXICO plc (IXI.L)
0.6$84.50+4.4%£39.83 million£9.53 million42.25
Tissue Regenix Group plc (TRX.L) logo
TRX
Tissue Regenix Group plc (TRX.L)
0.9$0.54+5.6%£37.98 million£13.05 million-1.35High Trading Volume
Gap Down
HEMO
Hemogenyx Pharmaceuticals Plc (HEMO.L)
0.4$8.60+4.7%£37.29 millionN/A-21.50
RUA
Rua Life Sciences Plc (RUA.L)
0.0$166.00+2.1%£36.83 million£835,000.00-20.24
FAB
Fusion Antibodies plc (FAB.L)
0.5$125.00+0.0%£31.80 million£4.05 million-41.67Insider Selling
Gap Up
ImmuPharma plc (IMM.L) logo
IMM
ImmuPharma plc (IMM.L)
0.6$11.78+0.3%£29.46 million£128,395.00-3.93Gap Up
COS
Collagen Solutions plc (COS.L)
0.6$6.63+0.0%£28.43 million£4.01 million-8.28
AOR
AorTech International
0.5$123.50+2.4%£21.85 million£539,000.00-33.38
Midatech Pharma plc (MTPH.L) logo
MTPH
Midatech Pharma plc (MTPH.L)
0.7$30.00+13.3%£18.92 million£390,000.00-0.32High Trading Volume
Gap Up
ValiRx plc (VAL.L) logo
VAL
ValiRx plc (VAL.L)
0.3$24.25+2.1%£15.73 millionN/A-1.35
RLM
Realm Therapeutics
0.6N/AN/A£13.41 million£501,919.00-0.66
NFX
Nuformix plc (NFX.L)
0.5$2.56+0.3%£13.35 million£195,550.00-12.79
OVB
Ovoca Bio plc (OVB.L)
0.7$10.75+0.0%£9.51 millionN/A-5.38Gap Down
Horizon Discovery Group plc (HZD.L) logo
HZD
Horizon Discovery Group plc (HZD.L)
1.3$5.51+3.8%£9.04 million£54.63 million-1.00Gap Down
PYC
Physiomics Plc (PYC.L)
0.4$8.00+2.5%£7.79 million£841,649.00-80.00
NSCI
NetScientific plc (NSCI.L)
0.6$50.50+0.0%£3.97 million£713,000.00-1.78
Motif Bio plc (MTFB.L) logo
MTFB
Motif Bio plc (MTFB.L)
0.6N/AN/A£3.28 millionN/A-0.18
SALV
SalvaRx Group
0.9$4.50+0.0%£1.65 million£64.50 million0.03Gap Down
PEBI
Port Erin Biopharma Investments
0.6$4.50+100.0%£1.04 million£28,300.00-6.43Gap Down
Abzena plc (ABZA.L) logo
ABZA
Abzena plc (ABZA.L)
0.6$15.75+0.0%£0.00N/A0.00
Vernalis plc (VER.L) logo
VER
Vernalis plc (VER.L)
0.7$6.17+0.0%£0.00N/A0.00
This page was last updated on 1/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.